We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer Canada today announced that its oral multi-targeted agent, Sutent (sunitinib malate) has been approved by Health Canada for the treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to intolerance or resistance.
Israeli drugmaker Teva Pharmaceutical has reported that a clinical trial indicated that Copaxone, the company's multiple sclerosis (MS) medication, was shown to be effective in patients who had stopped responding to Avonex, a competing drug made by Biogen Idec.
North Carolina-based Chelsea Therapeutics has entered into an exclusive license agreement with Japan's Dainippon Sumitomo Pharma (DSP) for the global development and commercialization rights to L-Threo DOPS (L-DOPS or Droxidopa), excluding Japan, Korea, China and Taiwan.
Sandoz, the generic drugs subsidiary of Swiss drugmaker Novartis, has reported that the U.S. FDA has the company's recombinant human growth hormone Omnitrope.
Japan-based Astellas Pharma has announced that its has terminated a license agreement with Les Laboratoires Servier, headquartered in France, regarding the anti-osteoporosis agent FK481 (strontium ranelate), which Astellas in-licensed from Servier.
Boasting strong price-competitiveness, Indian pharmaceutical firms specializing in generic products are increasingly targeting the fast-growing Japanese market.
Pharmaniaga Bhd is considering expanding its business into India in a move to meet growing demand in the pharmaceutical industry, its managing director Azhar Hussain said Tuesday.